Citation Impact
Citing Papers
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
2006 StandoutScience
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells
2005 StandoutNobel
Identification of the haematopoietic stem cell niche and control of the niche size
2003 StandoutNature
CD4+ Tregs and immune control
2004 StandoutNobel
Immunological aspects of cancer chemotherapy
2007
Transforming growth factor-β in T-cell biology
2002
Myeloid-derived suppressor cells coming of age
2018 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
HLA class I supertypes: a revised and updated classification
2008
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin
1989
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
2003
Cancer Metastasis: Building a Framework
2006 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
Mutations in the Human Orthologue of the Mouse underwhite Gene (uw) Underlie a New Form of Oculocutaneous Albinism, OCA4
2001
Immunology and immunotherapy approaches for prostate cancer
2007
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
1999
Antitumor Effect of OK-432–Derived DNA
2006
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Array-based genomic resequencing of human leukemia
2010
A listing of human tumor antigens recognized by T cells
2001
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
2014
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
2006
Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia
2002
A listing of human tumor antigens recognized by T cells: March 2004 update
2004
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
2006 StandoutNature
Single nucleotide polymorphisms in theMATP gene are associated with normal human pigmentation variation
2005
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Immunity, Inflammation, and Cancer
2010 Standout
The Biology of Chronic Myeloid Leukemia
1999
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Mice Defective in Two Apoptosis Pathways in the Myeloid Lineage Develop Acute Myeloblastic Leukemia
1998
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
2009
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
2020 Standout
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Pathobiology of chemotherapy-induced hair loss
2013
Evidence for Recent Positive Selection at the Human AIM1 Locus in a European Population
2005
New aspects of natural-killer-cell surveillance and therapy of cancer
2002
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
2000 StandoutNature
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Identification of human brain tumour initiating cells
2004 StandoutNature
The inflammatory reflex
2002 StandoutNature
Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer
2005
Genome-wide detection and characterization of positive selection in human populations
2007 StandoutNature
Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions
2005
Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells
2010 StandoutNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation
2000
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
2012 StandoutNobel
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation
2004
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
CD4+ Tregs and immune control
2004 StandoutNobel
Mice with Enhanced Macrophage Angiotensin-Converting Enzyme Are Resistant to Melanoma
2007 StandoutNobel
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Neuroendocrine Regulation of Immunity
2002
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients
2009
Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease
1999
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
2003
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
2003
The Sympathetic Nerve—An Integrative Interface between Two Supersystems: The Brain and the Immune System
2000 Standout
Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes
2013 StandoutNobel
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
2006
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity
2006 StandoutNobel
Works of Mamoru Harada being referenced
Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential
1997
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
2004
UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour
2002
Characterization of B16 melanoma-specific cytotoxic T lymphocytes
1998
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles
2006
Overexpression of interleukin‐15 in vivo enhances antitumor activity against mhc class I‐negative and ‐positive malignant melanoma through augmented NK activity and cytotoxic T‐cell response
2002
New Peptide Vaccine Candidates for Epithelial Cancer Patients With HLA-A3 Supertype Alleles
2007
Recognition of ADP‐ribosylation factor 4‐like by HLA‐A2‐restricted and tumor‐reactive cytotoxic T lymphocytes from patients with brain tumors
2002
Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes
2002
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
2004
Expression of Activation-Related Molecules on Regional Lymph Node Lymphocytes in Human Lung Cancer
1996
Vaccination of Cytotoxic T Lymphocyte-Directed Peptides Elicited and Spread Humoral and Th1-Type Immune Responses to Prostate-Specific Antigen Protein in a Prostate Cancer Patient
2005
Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery
2003
Melanoma-Reactive CD8 + T Cells Recognize a Novel Tumor Antigen Expressed in a Wide Variety of Tumor Types
2001
Contrasting effects of cyclophosphamide on anti‐CTL ‐associated protein 4 blockade therapy in two mouse tumor models
2017
Identification of Peptide Vaccine Candidates for Prostate Cancer Patients with HLA-A3 Supertype Alleles
2005
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients
2004
Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia
1996
Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
1997
Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
2006
Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
1998
Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
1995
IL-4-Producing NK1.1+ T Cells Are Resistant to Glucocorticoid-Induced Apoptosis: Implications for the Th1/Th2 Balance
1998
Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
2001
Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors
1988